5/22/2023 7:19:11 AM
Tonix Pharma Enters Research Collaboration Agreement To Evaluate The Effect Of TNX-1900
3/13/2023 7:21:18 AM
Tonix Pharma Q4 Net Loss Available To Stockholders $34.1 Mln Or $0.56/Shr Vs Loss Of $29.6 Mln Or $2.08/Shr Last Year
2/6/2023 7:18:55 AM
Tonix Pharma Begins Enrollment In Phase 2 PREVENTION Study Of Potentiated Intranasal Oxytocin
11/7/2022 7:43:37 AM
Tonix Pharma Q3 Net Loss Available To Stockholders $29.0 Mln Or $0.69/Shr Vs Loss Of $18.5 Mln Or $1.60/Shr Last Year
8/22/2022 7:37:39 AM
Tonix Pharma Begins Enrollment In Phase 2 PREVAIL Study Of TNX-102 SL For Treatment Of Long COVID
8/1/2022 7:25:47 AM
Tonix Pharma Announces Issuance Of U.S. Patent Covering TNX-1900 For Treatment Of Pain
6/27/2022 7:20:53 AM
Tonix Pharma Announces Design Of New Phase 2 Clinical Trial Of TNX-1300 For Cocaine Intoxication
5/23/2022 11:04:10 AM
Basler Shareholders Approve Agenda Items
5/18/2022 8:39:29 AM
Tonix Pharma Extends Research Collaboration With University Of Alberta To Develop Antiviral Drugs Against SARS-CoV-2
5/9/2022 9:04:36 AM
Tonix Pharma Q1 Loss Per Share $0.05 Vs Loss $0.07 Last Year
4/6/2022 7:56:13 AM
Tonix Pharma Announces IND Clearance For TNX-102 SL As A Potential Treatment For Long COVID Syndrome
3/3/2022 7:14:54 AM
Tonix Pharma: FDA Grants Orphan-Drug Designation For TNX-2900 For Prader-Willi Syndrome